Navigation Links
Hepatitis C therapy: Inhibiting newly discovered microDNA molecule

Last fall Dr. Peter Sarnow and a team of Stanford University scientists reported that the hepatitis C virus needs a specific microRNA, named miR-122, in order to replicate in cultured liver cells.

When the scientists inactivated the microRNA, the amount of hepatitis C virus RNA was reduced by approximately 80 percent. The discovery was widely heralded for its potential to develop new antiviral agents against hepatitis C, the most common blood-borne viral infection in the United States, affecting more than 2.5 million Americans and a staggering 170 million people worldwide. The best treatment regimens now available are difficult, expensive, laden with serious side effects and effective in only half the cases.

Dr. Sarnow discusses the most recent findings in this work on April 5 at Experimental Biology 2006 in San Francisco. His presentation is part of the scientific program of the American Society for Biochemistry and Molecular Biology.

MicroRNAs, or miRNAs for short, are small RNA molecules that regulate genes in many plant and animal species. Although miRNAs were not discovered until the mid-1990, a growing number of studies suggest that over 300 human genes encode microRNAs and that these microRNAs may control gene expression for as much as a third of the human genome, acting as key regulators of processes as diverse as early development, cell proliferation and cell death, and cell differentiation. Some miRNAs are located throughout the body, while others are found only in specific tissue. The miRNA whose surprising new role was discovered by Dr. Sarnow and his colleagues is located only in the liver. The Sarnow team found that miR-122 binds to a specific noncoding binding region in virus, called target 5' NCR. This is the first example of an animal RNA that interacts with its target 5' NCR, and opens an interesting possibility that other viral 5' NCRs are similarly targeted by different miRNAs.


'"/>

Source:Federation of American Societies for Experimental Biology


Page: 1

Related biology news :

1. Scientists Replicate Hepatitis C Virus in Laboratory
2. Norovirus, AIDS vaccine and Hepatitis Virus
3. UCLA study assesses cost-effectiveness of Hepatitis B drugs
4. Natural Killers Could Lead to New Hepatitis Treatments
5. FDA Approves New Treatment for Chronic Hepatitis B
6. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
7. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
8. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
9. Hepatitis C complicated by morphine withdrawal
10. Hepatitis B accounts for 40 percent of missing Asian women
11. Hepatitis E takes a piggyback
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
Breaking Biology Technology: